Centiva Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Centiva Capital’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-79,000	Closed	-$10.4M	–	2192
2025 Q1	$10.4M	Buy	+79,000	New	+$9.85M	0.31%	29
2023 Q2	–	Sell	-9,700	Closed	-$525K	–	2080
2023 Q1	$525K	Buy	+9,700	New	+$469K	0.01%	816

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Centiva Capital's ITCI Position: Q2 2025 in Review

Centiva Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 8,705 shares — an estimated $1.15M sold.

Centiva Capital first reported a position in ITCI in Q3 2021 and held it in 3 quarters. The position peaked at $1.15M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Centiva Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Centiva Capital sold 8,705 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $1.15M.
Centiva Capital first reported a position in Intra-Cellular Therapies Inc. in Q3 2021 and held it in 3 quarters.
Centiva Capital's Intra-Cellular Therapies Inc. position peaked at $1.15M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Centiva Capital's 13F filing for Q2 2025, filed 13 Aug 2025.